Rat Sirtuin 1 (SIRT1) Antibody Pair Kit (with Standard)
Cat# MBS2103228-5x96
Size : 5x96Tests
Marca : MyBiosource
Sirtuin 1 (SIRT1) Antibody Pair Kit for Rat
For Research Use Only. Not for use in diagnostic procedures. Special Promotion Catalog #: MBS2103228SPECIAL PROMOTION: Get FREE Starbucks gift card (Maximum 5 gift cards/product). Gift card(s) will be included with shipment
MBS2103228 is an antibody pair kit targeting SIRT1. Also known as Rat Sirtuin 1 (SIRT1) Antibody Pair Kit (with Standard). Reactive in Rat. More details
Product Overview
Online Datasheet in PDFProduct Name
Sirtuin 1 (SIRT1), Antibody Pair Kit
Full Product Name
Rat Sirtuin 1 (SIRT1) Antibody Pair Kit (with Standard)
Product Gene Name
SIRT1 antibody pair kit
Product Synonym Names
SIR2L1; Silent Mating Type Information Regulation 2 Homolog 1; NAD-Dependent Deacetylase Sirtuin-1; SIR2-like protein 1; SirtT1 75 kDa fragment
Species Reactivity
Rat
Samples
Tissue Homogenates, Cell Lysates and Other Biological Fluids
Detection Range
0.625-40ng/mL
Molecular Weight
61,066 Da
OMIM
AF083106 mRNA
Supply Chain Verification
Manufactured in a lab with traceable raw materials. Bulk orders can typically be prepared to the customer’s specifications, please inquire.
Standard
Recombinant SIRT1 (Lyophilized, 1 vial-10ug)
Capture Antibody
Rabbit polyclonal antibody (Liquid, 1 vial-400mug/800muL)
Detection Antibody
Biotinylated Rabbit polyclonal antibody (Liquid, 1 vial-100mug/500muL)
Producte Usage
Raw materials can be used for preparation of 5x96T or 10x96T ELISA Kits.
Antibody Support Pack
Antibody Support Pack (Buffer Pack) is sold separately as catalog #MBS2090685
Product Categories/Family for SIRT1 antibody pair kit
Endocrinology
ISO Certification
Manufactured in an ISO 9001:2015 and ISO 13485:2016 Certified Laboratory.
Applications Tested/Suitable for SIRT1 antibody pair kit
ELISA (EIA), Chemiluminescence Immunoassays (CLIA), ELISPOT, Luminex
Other Notes
Small volumes of SIRT1 antibody pair kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for SIRT1. It may not necessarily be applicable to this product.
NCBI Official Full Name
sirtuin 1, partial
NCBI Official Synonym Full Names
sirtuin 1
NCBI Official Symbol
SIRT1
NCBI Official Synonym Symbols
SIR2; SIR2L1; SIR2alpha
UniProt Protein Name
NAD-dependent protein deacetylase sirtuin-1
UniProt Synonym Protein Names
Regulatory protein SIR2 homolog 1; SIR2-like protein 1; hSIR2
Protein Family
NAD-dependent protein deacetylase sirtuin
UniProt Gene Name
SIRT1
UniProt Synonym Gene Names
SIR2L1; hSIRT1; hSIR2; 75SirT1
NCBI Protein Information
NAD-dependent protein deacetylase sirtuin-1
NCBI Summary for SIRT1
This gene encodes a member of the sirtuin family of proteins, homologs to the yeast Sir2 protein. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes. The functions of human sirtuins have not yet been determined; however, yeast sirtuin proteins are known to regulate epigenetic gene silencing and suppress recombination of rDNA. Studies suggest that the human sirtuins may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity. The protein encoded by this gene is included in class I of the sirtuin family. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2008]
Show more UniProt Comments for SIRT1
NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD+/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD+/NADP+ ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Modulates AP-1 transcription factor activity. Deacetylates NR1H3 AND NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and HMGCS1. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Deacetylates PML at 'Lys-487' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis (PubMed:11672523, PubMed:12006491, PubMed:14976264, PubMed:14980222, PubMed:15126506, PubMed:15152190, PubMed:15205477, PubMed:15469825, PubMed:15692560, PubMed:16079181, PubMed:16166628, PubMed:16892051, PubMed:16998810, PubMed:17283066, PubMed:17334224, PubMed:17505061, PubMed:17612497, PubMed:17620057, PubMed:17936707, PubMed:18203716, PubMed:18296641, PubMed:18662546, PubMed:18687677, PubMed:19188449, PubMed:19220062, PubMed:19364925, PubMed:19690166, PubMed:19934257, PubMed:20097625, PubMed:20100829, PubMed:20203304, PubMed:20375098, PubMed:20620956, PubMed:20670893, PubMed:20817729, PubMed:21149730, PubMed:21245319, PubMed:21471201, PubMed:21504832, PubMed:21555002, PubMed:21698133, PubMed:21701047, PubMed:21775285, PubMed:21807113, PubMed:21841822, PubMed:21890893, PubMed:21909281, PubMed:21947282, PubMed:22274616). Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity (PubMed:20955178). Involved in the CCAR2-mediated regulation of PCK1 and NR1D1 (PubMed:24415752). Deacetylates CTNB1 at 'Lys-49' (PubMed:24824780). In POMC (pro-opiomelanocortin) neurons, required for leptin-induced activation of PI3K signaling ().
Show more Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with SIRT1 antibody pair kit
| Reference Product | PubMed Publications |
|---|---|
| FOXO1 antibody pair kit | >119 publications with SIRT1 and FOXO1 |
| PPARGC1A antibody pair kit | >108 publications with SIRT1 and PPARGC1A |
| FOXO3 antibody pair kit | >51 publications with SIRT1 and FOXO3 |
| TP53 antibody pair kit | >37 publications with SIRT1 and TP53 |
| EP300 antibody pair kit | >17 publications with SIRT1 and EP300 |
| FOXO4 antibody pair kit | >11 publications with SIRT1 and FOXO4 |
| KAT5 antibody pair kit | >6 publications with SIRT1 and KAT5 |
| FHL2 antibody pair kit | >1 publications with SIRT1 and FHL2 |
| KAT2B antibody pair kit | >1 publications with SIRT1 and KAT2B |
| XRCC6 antibody pair kit | >1 publications with SIRT1 and XRCC6 |
Pathways associated with SIRT1 antibody pair kit
| Products by Pathway | Pathway Diagram |
|---|---|
| Amphetamine Addiction Pathway antibodies | Amphetamine Addiction Pathway Diagram |
| Amphetamine Addiction Pathway antibodies | Amphetamine Addiction Pathway Diagram |
| Androgen Receptor Signaling Pathway antibodies | Androgen Receptor Signaling Pathway Diagram |
| E2F Transcription Factor Network Pathway antibodies | E2F Transcription Factor Network Pathway Diagram |
| Energy Metabolism Pathway antibodies | Energy Metabolism Pathway Diagram |
| FoxO Family Signaling Pathway antibodies | FoxO Family Signaling Pathway Diagram |
| HIF-2-alpha Transcription Factor Network Pathway antibodies | HIF-2-alpha Transcription Factor Network Pathway Diagram |
| Integrated Breast Cancer Pathway antibodies | Integrated Breast Cancer Pathway Diagram |
| Integrated Pancreatic Cancer Pathway antibodies | Integrated Pancreatic Cancer Pathway Diagram |
| MicroRNAs In Cancer Pathway antibodies | MicroRNAs In Cancer Pathway Diagram |
Diseases associated with SIRT1 antibody pair kit
| Disease Name | Pubmed Publications |
|---|---|
| Neoplasms Antibodies | >300 publications with SIRT1 and Neoplasms |
| Cardiovascular Diseases Antibodies | >243 publications with SIRT1 and Cardiovascular Diseases |
| Inflammation Antibodies | >225 publications with SIRT1 and Inflammation |
| Insulin Resistance Antibodies | >161 publications with SIRT1 and Insulin Resistance |
| Neurodegenerative Diseases Antibodies | >139 publications with SIRT1 and Neurodegenerative Diseases |
| Liver Diseases Antibodies | >125 publications with SIRT1 and Liver Diseases |
| Brain Diseases Antibodies | >115 publications with SIRT1 and Brain Diseases |
| Fatty Liver Antibodies | >103 publications with SIRT1 and Fatty Liver |
| Heart Diseases Antibodies | >93 publications with SIRT1 and Heart Diseases |
| Necrosis Antibodies | >89 publications with SIRT1 and Necrosis |
Organs/Tissues associated with SIRT1 antibody pair kit
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Muscle Antibodies | >316 publications with SIRT1 and Muscle |
| Liver Antibodies | >302 publications with SIRT1 and Liver |
| Brain Antibodies | >232 publications with SIRT1 and Brain |
| Vascular Antibodies | >191 publications with SIRT1 and Vascular |
| Kidney Antibodies | >89 publications with SIRT1 and Kidney |
| Lung Antibodies | >88 publications with SIRT1 and Lung |
| Bone Antibodies | >63 publications with SIRT1 and Bone |
| Pancreas Antibodies | >58 publications with SIRT1 and Pancreas |
| Skin Antibodies | >43 publications with SIRT1 and Skin |
| Prostate Antibodies | >38 publications with SIRT1 and Prostate |


